PTC Therapeutics, Inc. Overview
Pro stress-test →PTC Therapeutics is a global biopharmaceutical company that discovers, develops and commercializes clinically differentiated medicines for children and adults living with rare disorders. The company guides 2026 product revenue of $700–$800M (excluding Evrysdi royalties) and reported 2025 product and royalty revenue of approximately $823.4M, with unaudited product revenue of about $587.8M.
Strategic Profile
Pro stress-test →With a $1.94 billion cash cushion, 2026 revenue guidance of $700–800 million and key FDA-aligned trials, PTC is funding growth while targeting cash-flow breakeven. The company's newly launched Sephience generated $112.1 million in 2025 net revenue since launch, with $92.5 million in fourth-quarter sales alone and reaching 946 patients worldwide by year-end.
Competitive Landscape
Pro stress-test →PTC focuses on rare disorder medicines leveraging its ability to innovate and globally commercialize products to support a diversified pipeline. Key competitors in rare disease include Roche/Genentech (with Evrysdi for SMA), Reata Pharmaceuticals (vatiquinone for Friedreich's ataxia), and Longevity Biotech (Huntington's disease programs). PTC's strategic positioning emphasizes multiple approved and pipeline programs across distinct rare indications.
Industry Context
PTC Therapeutics, Inc. operates in Biopharmaceutical - Rare/Orphan Diseases.
Key facts
Founded: 1998 · Headquarters: Warren, New Jersey, US · Revenue: $1.77B (TTM as of Feb 2026)